Background: Eastern American woodchuck (Marmota monax), naturally infected with woodchuck hepatitis virus, a virus similar to human hepatitis B virus, develops liver cancer with a high prevalence.
Aims: The aim of this work was to assess Marmota monax as a model of human hepatocellular carcinoma, especially to assess new potential adjuvant therapies after surgical resection.
Methods: Forty-four woodchuck hepatitis virus-infected animals were regularly screened by ultrasound examination from the age of 18 months and for a 30-month period. One or more liver tumors were diagnosed in 31 animals (70%). Five of them with multifocal tumor or poor general status were considered unsuitable for surgery. The other 26 were operated on. At laparotomy no tumor was found in three.
Results: The 18 liver tumors studied were hepatocellular carcinomas, grossly and microscopically similar to human hepatocellular carcinoma. Peritumoral parenchyma studied in 13 specimens was always non-cirrhotic but adequate staining demonstrated patterns of fibrosis in four cases. Clear evidence of chronic active hepatitis, periportal hepatitis and steatosis were demonstrated in five, seven and one of the 13 specimens, respectively. Tumors were treated by tumorectomy in eight animals, by alcoholization in seven and by laser photocoagulation in one. A simple tumor biopsy was performed in the other seven. Ten animals died postoperatively. All the survivors in the tumorectomy group died from tumor recurrence within 10-18 months after surgery.
Conclusions: It is concluded that woodchuck hepatitis virus-induced liver carcinoma is a natural model of human hepatocellular carcinoma with similar pathology and natural history, including early ultrasonic detection and tumor recurrence after resection. Tumor excision is feasible in this animal model, which now provides the basis for assessment of new potential adjuvant therapies for human hepatocellular carcinoma in an attempt to reduce the high recurrence rate after surgical resection in humans.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0168-8278(97)80468-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An optimized protocol for quality control of gene therapy vectors using nanopore direct RNA sequencing.
Genome Res
November 2024
Research Data Science Group, R&D, CSL, Parkville, Victoria 3000, Australia.
Article Synopsis
- * Nanopore direct RNA sequencing was found to be the best method for detecting RNA issues, including cryptic splicing and polyadenylation sites in lentiviral vectors.
- * This sequencing technique can help optimize vector design, leading to better quality and more reliable lentiviral gene therapies.
Sub-genomic flaviviral RNA elements increase the stability and abundance of recombinant AAV vector transcripts.
J Virol
August 2024
Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
Unlabelled: Many viruses have evolved structured RNA elements that can influence transcript abundance and translational efficiency, and help evade host immune factors by hijacking cellular machinery during replication. Here, we evaluated the functional impact of sub-genomic flaviviral RNAs (sfRNAs) known to stall exoribonuclease activity, by incorporating these elements into recombinant adeno-associated viral (AAV) genome cassettes. Specifically, sfRNAs from Dengue, Zika, Japanese Encephalitis, Yellow Fever, Murray Valley Encephalitis, and West Nile viruses increased transcript stability and transgene expression compared to a conventional woodchuck hepatitis virus element (WPRE).
View Article and Find Full Text PDFAn Open-Label Phase II Study Assessing the Safety of Bilateral, Sequential Administration of Retinal Gene Therapy in Participants with Choroideremia: The GEMINI Study.
Hum Gene Ther
August 2024
Biogen Inc., Cambridge, Massachusetts, USA.
Choroideremia, an incurable, progressive retinal degeneration primarily affecting young men, leads to sight loss. GEMINI was a multicenter, open-label, prospective, two-period, interventional Phase II study assessing the safety of bilateral sequential administration of timrepigene emparvovec, a gene therapy, in adult males with genetically confirmed choroideremia (NCT03507686, ClinicalTrials.gov).
View Article and Find Full Text PDFDeveloping Gene Therapy for Mitigating Multisystemic Pathology in Fabry Disease: Proof of Concept in an Aggravated Mouse Model.
Hum Gene Ther
September 2024
Takeda Pharmaceuticals USA, Inc., Cambridge, Massachusetts, USA.
Fabry disease (FD) is a multisystemic lysosomal storage disorder caused by the loss of α-galactosidase A (α-Gal) function. The current standard of care, enzyme replacement therapies, while effective in reducing kidney pathology when treated early, do not fully ameliorate cardiac issues, neuropathic manifestations, and risk of cerebrovascular events. Adeno-associated virus (AAV)-based gene therapies (AAV-GT) can provide superior efficacy across multiple tissues owing to continuous, endogenous production of the therapeutic enzyme and lower treatment burden.
View Article and Find Full Text PDFAnalysis of Replication, Cell Division-Mediated Spread, and HBV Envelope Protein-Dependent Pseudotyping of Three Mammalian Delta-like Agents.
Viruses
May 2024
Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Article Synopsis
- The human hepatitis delta virus (HDV) is a satellite virus that relies on hepatitis B virus (HBV) proteins for its assembly and targets the liver, and recent bioinformatics research has clarified its evolutionary origins and complexity.
- This study examines three mammalian HDV-like agents (DLAs) discovered in woodchuck, white-tailed deer, and lesser dog-like bat, focusing on their replication and ability to spread in various cell types.
- Findings indicate that these DLAs can replicate independently in both liver and non-liver tissues without needing helper virus envelope proteins, and their interactions with HBV proteins can lead to the formation of infectious particles for further study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!